ProCE Banner Activity

CME

Master Class in Personalized Myelofibrosis Care: New Evidence and Therapeutic Strategies to Improve Outcomes

Video

On-demand webcast of expert faculty presentation and case discussion on applying new evidence and therapeutic strategies to better personalize care for patients with myelofibrosis.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: December 18, 2023

Expiration: December 17, 2024

Share

Faculty

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Abdulraheem Yacoub

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp., Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.

CTI BioPharma Corp

Geron Corporation

GlaxoSmithKline LLC

Karyopharm Therapeutics Inc.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with myelofibrosis.

Program Learning Goal

This program will improve learners’ knowledge, confidence, competence, and performance in using evidence-based and guideline-directed best practices in the care of patients with myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify factors that contribute to cancer health disparities and may negatively affect outcomes for patients with MF

  • Incorporate available therapies into a best-practice strategy for first-line treatment of patients with MF based on available data and expert recommendations, taking risk stratification, molecular features, cytogenetics, and symptom burden into account

  • Plan evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy

  • Assess the toxicity profiles of current and emerging MF therapies to formulate an adverse event management plan to support quality of life and continuation of treatment

  • Recall new data on emerging agents to aid discussions of ongoing trial opportunities with eligible patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Jean-Jacques Kiladijan, MD, PhD: consultant/advisor/speaker: AbbVie, AOP Health, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, PharmaEssentia.

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Abdulraheem Yacoub, MD: consultant/advisor/speaker: AbbVie, Acceleron, Apellis, CTI Pharma, Gilead, Incyte, Notable Labs, Novartis, Pfizer, PharmaEssentia, Servier.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2023, through December 17, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.